Differential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model
Structural valve deterioration (SVD) of bioprosthetic heart valves (BHVs) has great clinical and economic consequences. Notably, immunity against BHVs plays a major role in SVD, especially when implanted in young and middle-aged patients. However, the complex pathogenesis of SVD remains to be fully characterized, and analyses of commercial BHVs in standardized-preclinical settings are needed for further advancement. Here, we studied the immune response to commercial BHV tissue of bovine, porcine, and equine origin after subcutaneous implantation into adult α1,3-galactosyltransferase-knockout (Gal KO) mice. The levels of serum anti-galactose α1,3-galactose (Gal) and -non-Gal IgM and IgG antibodies were determined up to 2 months post-implantation. Based on histological analyses, all BHV tissues studied triggered distinct infiltrating cellular immune responses that related to tissue degeneration. Increased anti-Gal antibody levels were found in serum after ATS 3f and Freedom/Solo implantation but not for Crown or Hancock II grafts. Overall, there were no correlations between cellular-immunity scores and post-implantation antibodies, suggesting these are independent factors differentially affecting the outcome of distinct commercial BHVs. These findings provide further insights into the understanding of SVD immunopathogenesis and highlight the need to evaluate immune responses as a confounding factor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Bioengineering (Basel, Switzerland) - 10(2023), 7 vom: 13. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Casós, Kelly [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α1,3-galactosyltransferase-knockout mice |
|---|
| Anmerkungen: |
Date Revised 31.07.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/bioengineering10070833 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360087299 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360087299 | ||
| 003 | DE-627 | ||
| 005 | 20231226082250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/bioengineering10070833 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360087299 | ||
| 035 | |a (NLM)37508860 | ||
| 035 | |a (PII)833 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Casós, Kelly |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Differential Immune Response to Bioprosthetic Heart Valve Tissues in the α1,3Galactosyltransferase-Knockout Mouse Model |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Structural valve deterioration (SVD) of bioprosthetic heart valves (BHVs) has great clinical and economic consequences. Notably, immunity against BHVs plays a major role in SVD, especially when implanted in young and middle-aged patients. However, the complex pathogenesis of SVD remains to be fully characterized, and analyses of commercial BHVs in standardized-preclinical settings are needed for further advancement. Here, we studied the immune response to commercial BHV tissue of bovine, porcine, and equine origin after subcutaneous implantation into adult α1,3-galactosyltransferase-knockout (Gal KO) mice. The levels of serum anti-galactose α1,3-galactose (Gal) and -non-Gal IgM and IgG antibodies were determined up to 2 months post-implantation. Based on histological analyses, all BHV tissues studied triggered distinct infiltrating cellular immune responses that related to tissue degeneration. Increased anti-Gal antibody levels were found in serum after ATS 3f and Freedom/Solo implantation but not for Crown or Hancock II grafts. Overall, there were no correlations between cellular-immunity scores and post-implantation antibodies, suggesting these are independent factors differentially affecting the outcome of distinct commercial BHVs. These findings provide further insights into the understanding of SVD immunopathogenesis and highlight the need to evaluate immune responses as a confounding factor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-Gal antibodies | |
| 650 | 4 | |a bioprosthetic heart valves | |
| 650 | 4 | |a cellular immune infiltrate | |
| 650 | 4 | |a structural valve deterioration | |
| 650 | 4 | |a α1,3-galactosyltransferase-knockout mice | |
| 700 | 1 | |a Llatjós, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Blasco-Lucas, Arnau |e verfasserin |4 aut | |
| 700 | 1 | |a Kuguel, Sebastián G |e verfasserin |4 aut | |
| 700 | 1 | |a Sbraga, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Cesare |e verfasserin |4 aut | |
| 700 | 1 | |a Padler-Karavani, Vered |e verfasserin |4 aut | |
| 700 | 1 | |a Le Tourneau, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Vadori, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Perota, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Roussel, Jean-Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Bottio, Tomaso |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzi, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Soulillou, Jean-Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Galiñanes, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Máñez, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Cristina |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioengineering (Basel, Switzerland) |d 2014 |g 10(2023), 7 vom: 13. Juli |w (DE-627)NLM259987786 |x 2306-5354 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:7 |g day:13 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/bioengineering10070833 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 7 |b 13 |c 07 | ||